Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857292 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2NMT1KCNH2CYP2D6TSHR | |
| SCHEMBL4396001 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1POLBKMT2ANMT1 | |
| SCHEMBL12424656 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL25067265 | 0.82 | TLR8 (0.59) | SMN1; SMN2ALDH1A1POLBKMT2ANMT1 | |
| SCHEMBL25067256 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL3038968 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL18250324 | 0.81 | TLR8 (0.57) | SMN1; SMN2ALDH1A1POLBKMT2ANMT1 | |
| SCHEMBL5824074 | 0.81 | TLR8 (0.57) | SMN1; SMN2ALDH1A1POLBKMT2ANMT1 | |
| SCHEMBL28078170 | 0.81 | TLR8 (0.57) | SMN1; SMN2ALDH1A1POLBKMT2ANMT1 | |
| Hydrochloric Acid SCHEMBL5133311 | 0.80 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1POLBKMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | SMN1; SMN2 3490/4885ALDH1A1 164/4885POLB 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.